***TASK*** the task is to summarize an input biomedical literature in six sentences 
    ***INPUT*** the input is a biomedical literature 
    ***OUTPUT*** the output is the summary of an input biomedical literature in six sentences 
    ***DOCUMENTATION*** 
    ***EXAMPLES*** 
    Input: BACKGROUND We analyzed the magnetic resonance imaging ( MRI ) responses by world health organization ( WHO ) , response evaluation criteria in solid tumor ( RECIST ) , European Association for the Study of Liver ( EASL ) , and modified RECIST ( mRECIST ) guidelines and correlated with survival after doxorubicin ( Adriamycin ; Pharmacia & Upjohn , Peapac , NJ ) . drug-eluting beads transarterial chemoembolization ( DEB TACE ) in patients with unresectable hepatocellular carcinoma ( HCC ) . PATIENTS AND METHODS The early target and overall imaging responses were studied in 120 consecutive patients treated with DEB TACE for unresectable HCC , using RECIST , WHO , EASL , and mRECIST guidelines on contrast-enhanced dynamic liver MRI . The median period between the DEB TACE and assessment scan was 33.50 days . Survival analyses were carried out with the Kaplan-Meier method and the Cox proportional model . RESULTS WHO and RECIST1.1 had poor correlation with survival . mRECIST and EASL had significant correlation with survival with target lesion response rates of 63.3 % and 48.3 % and with overall response rates of 52.5 % and 39.2 % , respectively . The responders of EASL and mRECIST had significant median survival ( P ≤ 0.0001 ) . Moreover , mRECIST was better than EASL in predicting survival , because the survival difference between responders and non-responders of overall response was statistically significant ( P = 0.013 ) for mRECIST , but not for EASL ( P = 0.064 ) . CONCLUSIONS EASL and mRECIST responses measured on MRI at an early time point after DEB TACE predicted survival . mRECIST response demonstrated higher survival correlation than EASL Purpose To evaluate the predictors of toxicity of drug-eluting beads loaded with irinotecan ( DEBIRI ) in the treatment of hepatic malignancies . Material s and Methods A total of 330 patients were enrolled in a prospect i ve , open-label , multicenter , multinational , single-arm study administering two types of drug-eluting beads ( DEBIRI and drug-eluting beads loaded with doxorubicin ) . Complications were grade d by Cancer Therapy Evaluation Program ’s Common Terminology Criteria for Adverse Events ( CTCAE ) version 3.0 . All events requiring additional physician treatment or requiring extended hospital stay or readmission within 30 days were included . Results A total of 109 patients received 187 DEBIRI treatments ( range 1 to 5 per patient ) . The most common histology was metastatic colorectal cancer in 76 % of patients , cholangiocarcinoma in 7 % of patients , and other metastatic disease in 17 % of patients . There were 35 patients ( 19 % ) with irinotecan treatments who sustained 158 treatment-related adverse events , with the median CTCAE event grade being CTCAE grade 2 ( range 1 to 5 ) . The most common adverse events were postembolic symptoms ( 42 % ) . Multivariate analysis identified pretreatment and treatment-related risk factors as follows : lack of pretreatment with hepatic arterial lidocaine ( p = 0.005 ) , ≥3 treatments ( p = 0.05 ) , achievement of complete stasis ( p = 0.04 ) , treatment with > 100 mg DEBIRI in 1 treatment ( p = 0.03 ) , and bilirubin > 2.0 μg/dl with > 50 % liver involvement ( p = 0.05 ) . These factors were predictive of adverse events and significantly greater hospital length of stay . Conclusions DEBIRI is safe when appropriate technique and treatment are used . Adverse events can be predicted based on pretreatment- and treatment-related factors , and their occurrence can become part of the informed consent process . Continued st and ardization of this treatment will lead to fewer adverse events and improved patient quality of life Purpose The phase II study was conducted to evaluate the efficacy and safety of irinotecan as salvage single-agent chemotherapy in patients with advanced pancreatic cancer . Methods Patients with measurable metastatic pancreatic cancer , progressive after previous gemcitabine-based chemotherapy were treated with irinotecan 150 mg/m2 every 2 weeks . Treatment was repeated until disease progression or unacceptable toxicity . Results Between March 2004 to February 2007 , 33 patients were registered and treated with irinotecan monotherapy . The patients ’ median age was 59 years ( range 36–70 ) and two had an ECOG performance status of 2 . A total of 167 chemotherapy cycles were delivered ( median , 4 ; range 2–12 ) . In an intent-to-treat analysis , three ( 9 % ) confirmed partial response and 13 patients with stable disease were observed for a disease control rate of 48 % . The median progression-free and overall survivals were 2.0 months ( 95 % CI , 0.7–3.3 ) and 6.6 months ( 95 % CI , 5.8–7.4 ) , respectively . Toxic effects were mainly gastrointestinal ( nausea in 64 % of patients , diarrhea in 36 % ) , Toxicity profiles were generally predictable and manageable , and there was no treatment-related death . Conclusions Second-line chemotherapy with single-agent irinotecan is marginally effective and well tolerated regimen for gemcitabine-pretreated patients with advanced pancreatic cancer 
    Output:
    
Transarterial DEBIRI is safe and effective in the treatment of unresectable CRLM to the liver .